世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

体外診断用酵素の市場規模、シェア、動向分析レポート:酵素タイプ別(ポリメラーゼ&トランスクリプターゼ、プロテアーゼ)、疾患タイプ別、技術タイプ別、最終用途別、地域別、セグメント別予測、2023年~2030年


In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme Type (Polymerase & Transcriptase, Proteases), By Disease Type, By Technology Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

体外診断用酵素市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の体外診断用酵素市場規模は、2023年から2030年にかけてCAGR 7.9%で拡大し、2030年には37億米ドルに達する見込みです... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月12日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
199 英語

1~3営業日


 

サマリー

体外診断用酵素市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の体外診断用酵素市場規模は、2023年から2030年にかけてCAGR 7.9%で拡大し、2030年には37億米ドルに達する見込みです。臨床疾患の正確で迅速な診断と治療は、最適な臨床結果を得るために不可欠である。注目すべき生体触媒特性により、酵素は幅広い疾患の診断に使用されている。

酵素バイオセンサーの開発は、臨床診断における酵素の有用性を高めている。臨床診断における必要性にもかかわらず、バイオセンサーの商業化と研究から臨床への移行はまだ低い。しかし、研究開発努力の増加に伴い、乳酸、コレステロール、グルコースバイオセンサーが診断用として製品化されている。

プロテアーゼは重要なシグナル伝達タンパク質であり、がん、神経疾患、炎症性疾患、心血管疾患など、いくつかの病理学的プロセスに不可欠である。ポリメラーゼとトランスクリプターゼ酵素は、予測期間中に最も速いCAGRを示すと予想される。さらに、これらの酵素を提供するプレーヤーが多数存在することが、成長を促進すると予想される。Kaneka Eurogentec S.A.、東洋紡株式会社、Sekisui Diagnostics, LLCなどの主要企業は、KOD DNA Polymerase、Taq DNA Polymerase、Tth DNA Polymerase、TTx DNA Polymeraseなど、幅広い種類のポリメラーゼを製造・販売している。

2019年は感染症分野が市場を支配した。COVID-19症例の世界的な急激な増加が、COVID-19診断用診断酵素の採用率を押し上げている。感染症診断のためのリアルタイムPCR、LAMP-PCR(Loop-mediated Isothermal Amplification-PCR)、マルチプレックスPCR、デジタルPCR技術に基づく定性的および定量的分子アッセイの利用可能性の増加が、このセグメントにおける酵素の需要を促進している。

酵素免疫組織化学(IHC)は、より優れたコントラスト比と、標的成分の検出のために複数のステインと使用できる手法の互換性により、組織学に好まれている。体外診断用医薬品(IVD)酵素は、組織検体や体液の分析のために、さまざまな最終用途で使用されている。一日に複数の分析を行う大規模な検査室から、少数の検査を行う小規模なクリニックまで、幅広いエンドユーザーが体外診断(IVD)用酵素を使用している。

北米は2019年に顕著な地域市場に浮上した。がん患者数の増加や生検サンプルの病理組織検査への酵素の採用は、同地域の市場成長を促進すると予想される他の要因の一部である。大規模な対象人口の存在、医療インフラの改善、満たされていない臨床ニーズの高さ、政府のイニシアチブの増加、高度な診断技術のための研究開発活動の増加は、最も速い成長率でアジア太平洋市場を牽引すると予測されている。

同市場の主要企業は、市場での存在感を高めるため、新製品の発売、買収、提携、パートナーシップ、地理的拡大などに取り組んでいる。例えば、2020年6月、Codexis, Inc.はAlphazyme LLCと高忠実度DNAポリメラーゼ、T7 RNAポリメラーゼ、逆転写酵素の製造と共同販売に関する提携契約を締結した。

体外診断用酵素市場レポートハイライト

- 酵素タイプ別では、ポリメラーゼと転写酵素が分子診断アッセイへの幅広い応用により、2022年に最大のシェアを占める

- 疾患タイプ別では、感染症分野が予測期間を通じて市場を支配する見込み

- 技術タイプ別では、がん診断における組織学的アッセイの有用性と、さまざまながん種の罹患率の上昇により、組織学的アッセイセグメントが2022年に最大のシェアを占めた。

- 最終用途別では、病院と診断ラボが2022年の市場を支配した。病院や診断ラボでは、入院患者の増加やがん患者の入院数の増加により、組織病理学や細胞病理学のための生検検体の流入が多い。

- この地域には、Innovative Research、Bio-Rad Laboratories, Inc.、Rockland Immunochemicals, Inc.、MyBioSource.com、RayBiotech, Inc.など、多数の企業が存在するため、2022年には北米が市場全体を支配した。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Enzyme Type
1.1.2. Disease Type
1.1.3. Technology Type
1.1.4. End use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Enzyme type outlook
2.2.2. Disease type outlook
2.2.3. Technology type outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. In-Vitro Diagnostics Enzymes Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. In-Vitro Diagnostics Enzymes Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. In-Vitro Diagnostics Enzymes: Product Estimates & Trend Analysis
4.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
4.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Proteases
4.3.1. Proteases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Polymerase & Transcriptase
4.4.1. Polymerase & Transcriptase market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Ribonuclease
4.5.1. Ribonuclease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. In-Vitro Diagnostics Enzymes: Disease Type Estimates & Trend Analysis
5.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
5.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Infectious Disease
5.3.1. Infectious Disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.1. COVID -19 Testing
5.3.1.1.1. COVID-19 testing market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.2. Hepatitis
5.3.1.2.1. Hepatitis market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.3. HIV
5.3.1.3.1. HIV market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.4. Others
5.3.1.4.1. Other testing market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Diabetes
5.4.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Oncology
5.5.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Cardiology
5.6.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Nephrology
5.7.1. Nephrology market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Autoimmune Diseases
5.8.1. Autoimmune diseases market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. In-Vitro Diagnostics Enzymes: Technology Estimates & Trend Analysis
6.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
6.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Histology Assays
6.3.1. Histology Assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Molecular Diagnostics
6.4.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.1. PCR Assays
6.4.1.1.1. PCR assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.2. NGS Assays
6.4.1.2.1. NGS assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.3. Others
6.4.1.3.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Clinical Chemistry
6.5.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. In-Vitro Diagnostics Enzymes : End Use Estimates & Trend Analysis
7.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
7.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Pharma & Biotech
7.3.1. Pharma & Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Hospital & Diagnostic Labs
7.4.1. Hospital & Diagnostic Lab market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Academic Labs
7.5.1. Academic Lab market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. In-Vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. In-Vitro Diagnostics Enzymes Market by Region: Key Marketplace Takeaway
8.3. North America
8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. U.K.
8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Merck KGaA
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Codexis, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Amano Enzymes Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Advanced Enzymes Technologies Ltd.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Biocatalysts Ltd.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Amicogen
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Dyadic International
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. BBI Solutions
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Affymetrix
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
9.2.11. American Laboratories
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Product benchmarking
9.2.11.4. Strategic initiatives

 

ページTOPに戻る


 

Summary

In-vitro Diagnostics Enzymes Market Growth & Trends

The global in-vitro diagnostics enzymes market size is expected to reach USD 3.70 billion by 2030, expanding at a CAGR of 7.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. Accurate and rapid diagnosis and treatment of clinical disorders are essential for optimal clinical outcomes. Owing to the noteworthy biocatalytic properties, enzymes are used in the diagnosis of a wide range of diseases.

The development of enzyme biosensors has increased the enzyme utility in clinical diagnostics. Despite the necessity in clinical diagnosis, the commercialization and translation of biosensors from research to clinics are still low. However, with an increase in R&D efforts, lactate, cholesterol, and glucose biosensors have been commercialized for diagnostic use.

Proteases are important signaling proteins that are critical to a few pathological processes, including cancer, neurological, inflammatory, and cardiovascular disorders. Polymerase and transcriptase enzymes are expected to exhibit the fastest CAGR over the forecast period. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the growth. Key players such as Kaneka Eurogentec S.A.; Toyobo Co., Ltd.; and Sekisui Diagnostics, LLC manufacture and distribute a wide range of polymerases, including KOD DNA Polymerase, Taq DNA Polymerase, Tth DNA Polymerase, and TTx DNA Polymerase.

The infectious disease segment dominated the market in 2019. An exponential rise in the COVID-19 cases globally drives the adoption rate of diagnostic enzymes for COVID-19 diagnosis. An increase in the availability of qualitative and quantitative molecular assays based on real-time PCR, Loop-mediated Isothermal Amplification- PCR (LAMP-PCR), multiplex PCR, and digital PCR technologies for the diagnosis of infectious diseases drives the demand for enzymes in this segment.

Enzymatic immunohistochemistry (IHC) is preferred for histology owing to a better contrast ratio and the method’s compatibility for use with multiple stains for the detection of target components. IVD enzymes are employed in different end-use settings for the analysis of tissue specimens and bodily fluids. A wide range of end users including large laboratories that conduct multiple analyses in a day and smaller clinics that conduct a few tests use enzymes for in-vitro diagnostics (IVD).

North America emerged as a prominent regional market in 2019. A rise in the number of cancer cases and the adoption of enzymes for histopathology of biopsy samples are some of the other factors expected to propel market growth in the region. The presence of a large target population, improvements in healthcare infrastructure, high unmet clinical needs, increase in government initiatives, and rise in R&D activities for advanced diagnostic techniques are anticipated to drive the Asia Pacific market with the fastest growth rate.

The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence. For instance, in June 2020, Codexis, Inc. signed a collaboration agreement with Alphazyme LLC for the manufacture and co-marketing of high-fidelity DNA polymerase, T7 RNA polymerase, and reverse transcriptase.

In-vitro Diagnostics Enzymes Market Report Highlights

• By enzyme type, polymerase and transcriptase enzymes held the largest share in 2022 owing to their wide applications in molecular diagnostic assays

• Based on disease type, the infectious disease segment is expected to dominate the market throughout the forecast period

• In terms of technology type, the histology assays segment held the largest share in 2022 owing to the utility of histology assays in cancer diagnostics, coupled with a rising incidence of different cancer types

• By end use, hospital and diagnostic labs dominated the market in 2022. They witness a high inflow of biopsy specimens for histopathology and cytopathology because of an increase in hospitalization and rise in the number of hospital admissions for cancer patients

• North America dominated the overall market in 2022 owing to the presence of a substantial number of players in this region including Innovative Research; Bio-Rad Laboratories, Inc.; Rockland Immunochemicals, Inc.; MyBioSource.com; and RayBiotech, Inc.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Enzyme Type
1.1.2. Disease Type
1.1.3. Technology Type
1.1.4. End use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Enzyme type outlook
2.2.2. Disease type outlook
2.2.3. Technology type outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. In-Vitro Diagnostics Enzymes Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. In-Vitro Diagnostics Enzymes Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. In-Vitro Diagnostics Enzymes: Product Estimates & Trend Analysis
4.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
4.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Proteases
4.3.1. Proteases market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Polymerase & Transcriptase
4.4.1. Polymerase & Transcriptase market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Ribonuclease
4.5.1. Ribonuclease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. In-Vitro Diagnostics Enzymes: Disease Type Estimates & Trend Analysis
5.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
5.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Infectious Disease
5.3.1. Infectious Disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.1. COVID -19 Testing
5.3.1.1.1. COVID-19 testing market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.2. Hepatitis
5.3.1.2.1. Hepatitis market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.3. HIV
5.3.1.3.1. HIV market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.1.4. Others
5.3.1.4.1. Other testing market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Diabetes
5.4.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Oncology
5.5.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Cardiology
5.6.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Nephrology
5.7.1. Nephrology market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Autoimmune Diseases
5.8.1. Autoimmune diseases market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. In-Vitro Diagnostics Enzymes: Technology Estimates & Trend Analysis
6.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
6.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Histology Assays
6.3.1. Histology Assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Molecular Diagnostics
6.4.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.1. PCR Assays
6.4.1.1.1. PCR assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.2. NGS Assays
6.4.1.2.1. NGS assays market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.3. Others
6.4.1.3.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Clinical Chemistry
6.5.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. In-Vitro Diagnostics Enzymes : End Use Estimates & Trend Analysis
7.1. In-Vitro Diagnostics Enzymes Market: Key Takeaways
7.2. In-Vitro Diagnostics Enzymes Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Pharma & Biotech
7.3.1. Pharma & Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Hospital & Diagnostic Labs
7.4.1. Hospital & Diagnostic Lab market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Academic Labs
7.5.1. Academic Lab market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. In-Vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. In-Vitro Diagnostics Enzymes Market by Region: Key Marketplace Takeaway
8.3. North America
8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. U.K.
8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Merck KGaA
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Codexis, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Amano Enzymes Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Advanced Enzymes Technologies Ltd.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Biocatalysts Ltd.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Amicogen
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Dyadic International
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. BBI Solutions
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Affymetrix
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
9.2.11. American Laboratories
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Product benchmarking
9.2.11.4. Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/08 10:26

154.13 円

166.76 円

202.76 円

ページTOPに戻る